Sierra Oncology Reports Positive Data from Phase 3 MOMENTUM Study

Jan 25, 2022 By MarketDepth

Biotechnology Business Headlines Healthcare Investing What's Hot

Cancer Research microscope and testtube

Sierra Oncology, Inc. (NASDAQ: SRRA) announced positive data from the pivotal Phase 3 MOMENTUM study.  The study housed a double blind clinical trial that evaluates momelotinib in myelofibrosis patients that are symptomatic and anemic and previously treated with an approved JAK inhibitor.  The trial has met all of its primary and key secondary endpoints.  “These data are extremely exciting and everything we had hoped to see from the trial,” said Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra Oncology. “To achieve statistically significant and clinically important efficacy across all prespecified primary and key secondary endpoints while maintaining platelet counts in such a difficult to treat patient population is remarkable, and a confirmation of the anemia response we identified in the comprehensive review of our previous Phase 3 studies.”

“As a clinician, I am thrilled to see data that confirm the potential of momelotinib as a treatment option for myelofibrosis patients who are anemic or at risk of becoming anemic. Anemia of myelofibrosis is strongly correlated with reduced quality of life and a decrease in overall survival. Half of all myelofibrosis patients present with anemia at diagnosis and virtually all become anemic over time. With currently approved therapies being myelosuppressive, it’s wonderful to know that we may soon have such an effective treatment option for these patients.”

Ruben Mesa, MD, FACP, Executive Director of the Mays Cancer Center, home to UT Health San Antonio, MD Anderson Cancer Center, and co-Principal Investigator of the study

The data was produced from 195 patients.  Barbara Klencke, MD, Chief Medical Officer of Sierra Oncology, stated, “We are committed to working tirelessly to bring momelotinib to patients as quickly as possible.We would like to thank the patients and investigators who participated in this study and look forward to presenting the full data set at an upcoming medical meeting.”